Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. (Q39904021)

15 September 2017

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. (English)

1 reference

15 September 2017

Hagop Youssoufian

1

1 reference

15 September 2017

Eric K Rowinsky

series ordinal

2

1 reference

15 September 2017

James Tonra

series ordinal

3

1 reference

15 September 2017

Yiwen Li

series ordinal

4

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

15 September 2017

1 reference

15 September 2017

116

1 reference

15 September 2017

4 Suppl

1 reference

15 September 2017

1013-1017

1 reference

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

15 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Flt3 mutations and leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

FLT3 tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Monoclonal antibody-based therapeutics for leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24787

7 January 2021

Identifiers

DOI

10.1002/CNCR.24787

1 reference

15 September 2017

1 reference